30.01.2024 - SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) - Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of .
19.01.2024 - SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) - Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement to acquire select assets from Intermountain . Seite 1
31.10.2023 - SALT LAKE CITY, Oct. 31, 2023 (GLOBE NEWSWIRE) - Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Monday, November 6, 2023 at 4:30 p.m. EDT. The .
26.10.2023 - Partnership covers development of lab-developed and distributable kit-based companion diagnostic testsCombined strengths in assay development, clinical testing, and regulatory approvals offers pharma partners comprehensive global companion . Seite 1